Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Schroders outlines new three-year strategy, FY24 profits down

(Sharecast News) - Asset manager Schroders detailed its new three-year strategy alongside its FY24 earnings on Thursday as it stated it would now look to draw in new business and curtail rising costs. Schroders said it will look to deliver £150.0m of annualised net cost savings over the next three years and claims it has already delivered £20.0m worth of savings in Q124.

The FTSE 100-listed group will also look to stabilise revenues in public markets, generate cumulative net new business of £20.0bn in Schroders Capital, and achieve a net new business rate in its Wealth Management arm of 5-7% of opening assets under management per year. Schroders said this will reduce its adjusted cost:income ratio from 75% to less than 70%.

Schroders also revealed profits had fallen 3% in FY24 to £640.5m due to higher operating expenses, lower performance fees and reduced returns from joint ventures and associates.

Assets under management ticked up 4% to £778.8bn, while net operating revenues, excluding performance fees and net carried interest, were up 2% at £2.29bn. Statuatroy pre-tax profits were 14% stronger at £558.1m.

Chief executive Richard Oldfield said: "We will re-focus on our considerable areas of strength and have a firm grip on our challenges. Our transformation plan is underway, and will benefit not just our shareholders, but also our people and, most importantly, our clients. We have a strong balance sheet and will deploy our resources and capital rigorously."

As of 0920 GMT, Schroders shares were up 2.61% at 761.60p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.